Literature DB >> 20735162

Defining the risks of mesenchymal stromal cell therapy.

Darwin J Prockop1, Malcolm Brenner, Willem E Fibbe, Edwin Horwitz, Katarina Le Blanc, Donald G Phinney, Paul J Simmons, Luc Sensebe, Armand Keating.   

Abstract

Abstract We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.

Mesh：

Substances：

Year:  2010        PMID： 20735162     DOI： 10.3109/14653249.2010.507330

Source DB:  PubMed          Journal:  Cytotherapy        ISSN： 1465-3249            Impact factor:   5.414


  115 in total

Review 1.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

Review 2.  Mesenchymal stem cells in the pathogenesis and therapy of breast cancer.

Authors:  Christelle P El-Haibi; Antoine E Karnoub
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-12-21       Impact factor: 2.673

Review 3.  Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation.

Authors:  Darwin J Prockop; Joo Youn Oh
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 4.  Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012.

Authors:  Daniel J Weiss
Journal:  Ann Am Thorac Soc       Date:  2013-10

Review 5.  Immunomodulation by mesenchymal stem cells in veterinary species.

Authors:  Danielle D Carrade; Dori L Borjesson
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

Review 6.  Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures.

Authors:  Karen Bieback
Journal:  Transfus Med Hemother       Date:  2013-08-26       Impact factor: 3.747

7.  Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

Authors:  Moa Fransson; Elena Piras; Hao Wang; Joachim Burman; Ida Duprez; Robert A Harris; Katarina LeBlanc; Peetra U Magnusson; Eva Brittebo; Angelica S I Loskog
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 8.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

9.  Protective Effect of Mesenchymal Stem Cells Against the Development of Intracranial Aneurysm Rupture in Mice.

Authors:  Atsushi Kuwabara; Jia Liu; Yoshinobu Kamio; Airan Liu; Michael T Lawton; Jae-Woo Lee; Tomoki Hashimoto
Journal:  Neurosurgery       Date:  2017-12-01       Impact factor: 4.654

10.  HCELL Expression on Murine MSC Licenses Pancreatotropism and Confers Durable Reversal of Autoimmune Diabetes in NOD Mice.

Authors:  Reza Abdi; Robert Moore; Shinobu Sakai; Conor B Donnelly; Marwan Mounayar; Robert Sackstein
Journal:  Stem Cells       Date:  2015-05       Impact factor: 6.277
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.